2) The development of the first anticancer targeted therapy to the Bcr/Abl gene product, a fusion protein that produces a constitutively active non-receptor tyrosine kinase that drives proliferation of Chronic Myelogenous Leukemia (CML) cells. Here, NTRK1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.